More about Jubilant Ingrevia Limited
Fundamentals for Jubilant Ingrevia Limited
Regulatory Filings for Jubilant Ingrevia Limited
Apollo FY26: When Healthcare Becomes a Flywheel
NITI Blueprint Could Turn Brain Drain Into $135Bn Engine
RAINMUMBAI Turns Rain Into a Financial Asset
India’s IT Sector Faces a Historic Breaking Point
Fundamentals for Jubilant Ingrevia Limited
Business Operations:
Sector: Basic MaterialsIndustry: Specialty Chemicals
Jubilant Ingrevia Limited engages in the life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. The company provides piperidines, metal complexes, choline salts, vitamin B3, Vitamin B4, picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, formaldehyde, bio acetic acid-food grade, acetaldehyde, and ethanol, as well as cyano, acetyl, amino, halo, alkyl, and aldehyde pyridines. In addition, it offers route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.
Revenue projections:
JUBLINGREA's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 23.458408 |
| debtToEquity | 26.510000 |
| earningsGrowth | -0.323000 |
| revenueGrowth | -0.005000 |
| grossMargins | 0.473820 |
| operatingMargins | 0.077560 |
| trailingEps | 16.760000 |
| forwardEps | 29.714290 |
Jubilant Ingrevia Limited's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
JUBLINGREA's low Debt-to-Equity ratio reflects that the company isn't heavily reliant on debt, reducing financial risk. This conservative approach suggests JUBLINGREA maintains a stable financial foundation, with greater flexibility to manage future growth or challenges without over-leverage concerns.
JUBLINGREA's low earnings and revenue growth suggest that the company may face shrinking profits. This could indicate underlying financial challenges, making it difficult for JUBLINGREA to sustain its current profitability.
JUBLINGREA's negative gross and operating margins indicate that the company is not generating profit from either production or day-to-day operations. This could suggest cost overruns or declining revenue, impacting its financial stability.
JUBLINGREA's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that JUBLINGREA is projected to improve its financial performance compared to the previous year.
Price projections:
The stock price of JUBLINGREA has often been near the lower end of projections, indicating that it may not be meeting investor expectations. This trend could suggest challenges ahead for the company.
Insider Transactions:
Jubilant Ingrevia Limited experienced 2 selling transactions, with market price of 686.4500122070312.JUBLINGREA had 20 buy transactions while market price was at 644.4275024414062 per share.JUBLINGREA's current price levels are experiencing more selling than buying, which may suggest further declines. If the trend persists, it could lead to a continued downward trajectory as investors lose confidence in the stock's future performance.
Recommendation changes over time:
JUBLINGREA has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see JUBLINGREA as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
How Independent Directors Failed Rs 2,500 Crore in Value
India’s Stock Market May Be Sitting on a Trap